|
Revenue from continuing operations fell by 2.7% year on year to Rs 787.45 crore during the quarter. A robust underlying volume growth was offset by the impact of National List of Essential Medicines (NLEM) 2022.
Profit before exceptional item and tax increased 0.09% to 176.90 crore in Q4 FY23 as compared with Rs 176.74 crore in Q4 FY22. Exceptional items stood at Rs 10.40 crore in Q4 FY23.
GSK Pharma's consolidated net profit declined 64% to Rs 610.69 crore in FY23 from Rs 1,694.72 crore in FY22. Net sales fell marginally to Rs 3,251.72 crore in FY23 over FY22.
Profit Before Tax (PBT) from continuing operations (before exceptional items) grew 9% to Rs 833 crore. The EBITDA margins improved by 1.4% compared to the previous fiscal with continued focus on improving operational efficiencies and expenditure control.
The company continued to maintain market leadership in therapies such as Dermatology and Pain. The self-pay vaccines market continued to decline year on year with early signs of recovery.
Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals, said, “GSK remains focused on gaining share and defending leadership position of key brands for therapies in which we operate. With the launch of our global blockbuster Shingrix we expect to address an unmet preventive health need and gain momentum for our vaccines business.”
The board has declared the dividend of Rs 32 per equity share for financial year 2023-2022.
GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.
The scrip declined 0.55% to Rs 1,284.60 on the BSE.
|